The underlying neurobiological basis of major depressive disorder remains elusive due to
the severity, complexity, and heterogeneity of the disorder. While the traditional …

Current therapeutic options for major depressive disorder (MDD) and bipolar disorder (BD)
are associated with a lag of onset that can prolong distress and impairment for patients, and …

Large 'real world'studies demonstrating the limited effectiveness and slow onset of clinical
response associated with our existing antidepressant medications has highlighted the need …

Hypofunctioning of the N-methyl-D-aspartate receptor (NMDA-R) has been prominently
implicated in the pathophysiology of schizophrenia (ScZ). The current study tested the …

The pharmacological modulation of glutamatergic neurotransmission to improve cognitive
function has been a focus of intensive research, particularly in relation to the cognitive …

Rationale Aberrant prefrontal-hippocampal (PFC-HC) connectivity is disrupted in several
psychiatric and at-risk conditions. Advances in rodent functional imaging have opened the …

Systemic doses of the psychotomimetic ketamine alter the spectral characteristics of
hippocampal and prefrontal cortical network activity. Using dynamic causal modeling (DCM) …

Brain changes in schizophrenia evolve along a dynamic trajectory, emerging before disease
onset and proceeding with ongoing illness. Recent investigations have focused attention on …

Objective Studies of the effects of the N-methyl-d-aspartate (NMDA) glutamate receptor
antagonist, ketamine, have suggested similarities to the symptoms of schizophrenia. Our …

Considerable evidence implicates DISC1 as a susceptibility gene for multiple psychiatric
diseases. DISC1 has been intensively studied at the molecular, cellular and behavioral …